Scemblix

Chemical Nameasciminib
Dosage FormFilm-coated tablets (oral; 20 mg, 40 mg
Drug ClassKinase inhibitors
SystemBlood
CompanyNovartis
Approval Year2021

Indication

  • For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs)
  • For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation
Last updated on 3/28/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Scemblix (asciminib) Prescribing Information.2021Novartis Pharmaceuticals Corporation, East Hanover, NJ